Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.

ABSTRACT:

Background

LRIG1, the founding member of the LRIG (leucine-rich repeat and immunoglobulin-like domain) family of transmembrane proteins, is a negative regulator of receptor tyrosine kinases and a tumour suppressor. Decreased LRIG1 expression is consistently observed in cancer, across diverse tumour types, and is linked to poor patient prognosis. However, mechanisms by which LRIG1 is repressed are not fully understood. Silencing of LRIG1 through promoter CpG island methylation has been reported in colorectal and cervical cancer but studies in breast cancer remain limited.

Methods

In silico analysis of human breast cancer patient data were used to demonstrate a correlation between DNA methylation and LRIG1 silencing in basal/triple-negative breast cancer, and its impact on pat

SUBMITTER: Umeh-Garcia M 

PROVIDER: S-EPMC9346006 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature